Nymox Pharmaceutical NXC-4720 Reduces E. Coli Contamination By 99%

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing is developing NXC-4720, the Company’s innovative new product targeting E. coli O157:H7 food poisoning at its source: the contamination of food products. Studies have shown that NXC-4720 is capable of reducing the level of E. coli O157:H7 contamination by over 99%.

Back to news